系统综述与Meta分析:克罗恩病诱导和维持试验中的安慰剂率
该系统综述与Meta分析检索MEDLINE、EMBASE和CENTRAL至2014年4月,纳入100项安慰剂对照试验(含67个诱导期和40个维持期,共7638名参与者),评估克罗恩病诱导和维持试验的安慰剂缓解率与应答率及其影响因素。
要点
- 诱导试验汇总安慰剂缓解率为18%(95%CI 16-21%),应答率为28%(95%CI 24-32%)。
- 维持试验汇总安慰剂缓解率为32%(95%CI 25-39%),应答率为26%(95%CI 19-35%)。
- 安慰剂率因试验设计(诱导或维持)及终点(缓解或应答)不同而异,影响因素各异。
核心结论
- 安慰剂率因试验设计为诱导或维持而不同,且影响缓解与应答终点的因素各异,这些发现对克罗恩病临床试验设计具有重要意义。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和CENTRAL自建库至2014年4月,纳入100项克罗恩病药物干预的安慰剂对照试验,含67个诱导期和40个维持期,共7638名参与者。
主要发现
- 诱导试验汇总安慰剂缓解率为18%(95%CI 16-21%),应答率为28%(95%CI 24-32%)。
- 维持试验汇总安慰剂缓解率为32%(95%CI 25-39%),应答率为26%(95%CI 19-35%)。
- 缓解方面,纳入疾病活动度更重、病程更长和研究中心更多的试验与更低的安慰剂率相关,而更多研究访视和更长研究时长与更高的安慰剂率相关。
- 应答方面,结果相反,纳入疾病活动度更轻和更长研究时长的试验与更低的安慰剂率相关。
- 安慰剂率因药物类别和给药途径而异,生物制剂观察到最高的安慰剂应答率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimising placebo response is essential for drug development. AIM: To conduct a meta-analysis to determine placebo response and remission rates in trials and identify the factors affecting these rates. METHODS: MEDLINE, EMBASE and CENTRAL were searched from inception to April 2014 for placebo-controlled trials of pharmacological interventions for Crohn's disease. Placebo response and remission rates for induction and maintenance trials were pooled by random-effects and mixed-effects meta-regression models to evaluate effects of study-level characteristics on these rates. RESULTS: In 100 studies containing 67 induction and 40 maintenance phases and 7638 participants, pooled placebo remission and response rates for induction trials were 18% [95% confidence interval (CI) 16-21%] and 28% (95% CI 24-32%), respectively. Corresponding values for maintenance trials were 32% (95% CI 25-39%) and 26% (95% CI 19-35%), respectively. For remission, trials enrolling patients with more severe disease activity, longer disease duration and more study centres were associated with lower placebo rates, whereas more study visits and longer study duration was associated with higher placebo rates. For response, findings were opposite such that trials enrolling patients with less severe disease activity and longer study duration were associated with lower placebo rates. Placebo rates varied by drug class and route of administration, with the highest placebo response rates observed for biologics. CONCLUSIONS: Placebo rates vary according to whether trials are designed for induction or maintenance and the factors influencing them differ for the endpoints of remission and response. These findings have important implications for clinical trial design in Crohn's disease.
引用
- Jairath V, Zou G, Parker CE, et al. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Aliment Pharmacol Ther. 2017. PMID: 28164348. doi:10.1111/apt.13973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。